PARIET® Tablets

PRODUCT INFORMATION
NAME OF THE DRUG
Rabeprazole sodium

DESCRIPTION
Rabeprazole sodium is a substituted benzimidazole and belongs to the class of proton pump
inhibitors. Its solubility in water is pH dependent, being very soluble in water at pH 9 to 11, and
only slightly soluble in water at pH 8. It is very soluble in methanol, freely soluble in
dichloromethane and practically insoluble in hexane.
The chemical name for rabeprazole sodium is (±) 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-
yl}-methylsulphinyl]-1H-benzimidazole sodium. Rabeprazole has one chiral centre and is a
racemate of two enantiomers. It has the following structural formula:

C 18 H 20 N 3 NaO 3 S MW: 381.43

CAS-117976-89-3 (rabeprazole) CAS-117976-90-6 (rabeprazole sodium)

PARIET is available as enteric coated tablets containing 10 mg rabeprazole sodium (equivalent

to 9.42 mg rabeprazole) or 20 mg rabeprazole sodium (equivalent to 18.85 mg rabeprazole).

PARIET tablets contain the inactive ingredients mannitol, magnesium oxide, hyprolose,
magnesium stearate, ethylcellulose, hypromellose phthalate, diacetylated monoglycerides,
purified talc, titanium dioxide and carnauba wax. The 10 mg tablet also contains iron oxide red
and Edible Ink Gray F6 and the 20 mg tablet contains iron oxide yellow and Edible Ink Red A1.

PHARMACOLOGY
Rabeprazole sodium suppresses gastric acid secretion by the specific inhibition of the H+/K+-
ATPase enzyme (proton pump) at the secretory surface of the gastric parietal cell thereby blocking
the final step of acid production. This effect is dose-related and leads to inhibition of both basal
and stimulated acid secretion irrespective of the stimulus. Animal studies indicate that after
administration, rabeprazole sodium rapidly disappears from both the plasma and gastric mucosa.

CCDS 180622 1 PARIET (190617) API

Pharmacodynamics
Anti-Secretory Activity: Oral administration of a 20 mg dose of PARIET provides rapid and
effective reduction of gastric acid secretion. The onset of the anti-secretory effect occurs within
one hour with the maximum effect occurring within two to four hours. Inhibition of basal and food-
stimulated acid secretion 23 hours after the first dose of rabeprazole sodium is 69% and 82%
respectively, and the duration of inhibition lasts up to 48 hours. The duration of pharmacodynamic
action is much longer than the pharmacokinetic half-life (approximately one hour) would predict.
This effect is probably due to the prolonged binding of rabeprazole sodium to the parietal H+/K+-
ATPase enzyme. The inhibitory effect of rabeprazole sodium on acid secretion increases slightly
with repeated once daily dosing, achieving steady state inhibition after three days. When the drug
is discontinued, secretory activity normalises over 2 to 3 days.
Helicobacter pylori is associated with duodenal and gastric ulcer disease in approximately 95%
and 70% of patients respectively. H. pylori is implicated as a major contributing factor in the
development of gastritis and ulcers in such patients. Recent evidence also suggests a causative
link between H. pylori and gastric carcinoma. H. pylori eradication therapy is appropriate in most
patients with duodenal and gastric ulcer where the latter is not caused by nonsteroidal anti-
inflammatory drug (NSAID) ingestion (see DOSAGE AND ADMINISTRATION).
Serum Gastrin Effects: In clinical studies, patients were treated once daily with 10 or 20 mg
rabeprazole sodium for up to 12 months duration. Serum gastrin levels increased during the first
2 to 8 weeks reflecting the inhibitory effects on acid secretion. Gastrin values returned to pre-
treatment levels, usually within 1 to 2 weeks after discontinuation of therapy. In a maintenance
study, which was subsequently extended up to 5 years duration, serum gastrin levels were only
modestly raised in most patients.
Enterochromaffin-Like (ECL) Cell Effects: Increased serum gastrin secondary to antisecretory
agents stimulates proliferation of gastric ECL cells which, over time, may result in ECL cell
hyperplasia in rats and mice and gastric carcinoids in rats, especially females (see
Carcinogenicity, Mutagenicity and Impairment of Fertility).
In over 400 patients treated with PARIET (10 or 20 mg/day) for up to one year, the incidence of
ECL cell hyperplasia increased with time and dose, which is consistent with the pharmacological
action of the proton pump inhibitor. No patient developed the adenomatoid, dysplastic or
neoplastic changes of ECL cells in the gastric mucosa. No patient developed the carcinoid
tumours observed in rats.
Pharmacokinetics
Absorption: PARIET tablets are enteric coated to allow rabeprazole sodium, which is acid labile,
to pass through the stomach intact. Absorption is rapid, with peak plasma levels of rabeprazole
sodium occurring approximately 3.5 hours after a 20 mg dose. Peak plasma concentrations
(C max) of rabeprazole sodium and AUC are linear over the dose range of 10 mg to 40 mg.
Absolute bioavailability of an oral 20 mg dose (compared to intravenous administration) is about
52%, largely due to pre-systemic metabolism. Additionally, the bioavailability does not appear to
increase with repeat administration. In healthy subjects, the plasma half-life is approximately one
hour (range 0.7 to 1.5 hours) and the total body clearance is estimated to be 283 ± 98 mL/min.
Distribution: Rabeprazole sodium is approximately 97% bound to human plasma proteins. After
intravenous administration the volume of distribution is 0.34 L/kg.
Metabolism: Rabeprazole sodium is metabolised through the cytochrome P450 (CYP450)
hepatic drug metabolism system (see Interactions with Other Drugs). In humans, the thioether
(M1) and carboxylic acid (M6) are the main plasma metabolites with the sulphone (M2), desmethyl
thioether (M4) and mercapturic acid conjugate (M5) minor metabolites observed at lower levels.
Only the desmethyl metabolite (M3) has a small amount of anti-secretory activity, but its presence
in plasma is minimal.

CCDS 180622 2 PARIET (190617) API

Elimination and Excretion: Following a single 20 mg 14C-labelled oral dose of rabeprazole sodium,
no unchanged drug was excreted in the urine. Approximately 90% of the dose was eliminated in
urine mainly as the two metabolites: a mercapturic acid conjugate (M5) and a carboxylic acid
(M6), plus two unknown metabolites also found in the species used in the toxicology studies. The
remainder of the dose was recovered in faeces. Total recovery was 99.8%. This suggests low
biliary excretion of the metabolites; with bio-transformation and urinary excretion of water soluble
metabolites as the primary route of elimination.
Special populations
Renal Disease: In patients with stable, end-stage, renal failure requiring maintenance
haemodialysis (creatinine clearance ≤ 5 mL/min/1.73 m2), the pharmacokinetics of rabeprazole
sodium was very similar to that in healthy volunteers.
Hepatic Disease: In a single dose study of 10 patients with chronic mild to moderate compensated
cirrhosis of the liver who were administered a 20 mg dose of rabeprazole, AUC 0-24 was
approximately doubled, the elimination half-life was 2- to 3-fold higher, and total body clearance
was decreased to less than half compared to values in healthy men.
In a multiple dose study of 12 patients with mild to moderate hepatic impairment administered 20
mg rabeprazole once daily for eight days, AUC 0-∞ and C MAX values increased approximately 30%
compared to values in healthy age- and gender-matched subjects. These increases were not
statistically significant.
No information exists on rabeprazole disposition in patients with severe hepatic impairment.
Please refer to the DOSAGE AND ADMINISTRATION section for information on dosage
adjustments in patients with hepatic impairment.
Geriatrics: Elimination of rabeprazole sodium was decreased in the elderly. Following 7 days of
daily dosing with 20 mg of rabeprazole sodium, the AUC approximately doubled and the Cmax
increased by 60% as compared to young healthy volunteers. However, there was no evidence
of rabeprazole sodium accumulation.

CLINICAL TRIALS
At the time of registration, more than 3000 patients in the US, Europe and Japan had received
rabeprazole sodium in both controlled and uncontrolled clinical studies.
The efficacy of PARIET was assessed in nine double-blind, controlled, randomised, parallel group
primary efficacy trials in patients with duodenal ulcer, gastric ulcer and gastro-oesophageal reflux
disease. Three trials were conducted in each indication, a placebo controlled study and
comparative studies with either ranitidine or omeprazole. In all these studies the primary efficacy
variable used was ulcer or ulcerative GORD healing rates as determined by endoscopic
examination.
A further three clinical trials were conducted to establish efficacy of rabeprazole in the long-term
prevention of relapse of gastro-oesophageal reflux disease. Two studies were placebo controlled,
whilst the other was actively controlled with omeprazole. In all three studies the primary efficacy
variable used was the continued absence of oesophageal erosions or ulcerations as determined
by endoscopic examination.
Treatment of Erosive or Ulcerative Gastro-Oesophageal Reflux Disease (GORD): In the
placebo-controlled study, 103 patients were treated for up to eight weeks either with placebo or
PARIET 10, 20 or 40 mg once daily (od). PARIET was significantly superior to placebo in
producing endoscopic healing after four and eight weeks of treatment (p<0.001).
PARIET 20 mg once daily was also significantly more effective than placebo in terms of symptom
relief, providing complete resolution of heartburn frequency, daytime heartburn severity, and
decreasing the amount of antacid taken per day after four and eight weeks of treatment.
PARIET 20 mg once daily was statistically superior to ranitidine 150 mg four times per day with
respect to the percentage of patients healed at endoscopy and in symptom relief. PARIET was
also significantly more effective than ranitidine in terms of providing complete resolution of
heartburn frequency, and daytime and night-time heartburn severity; after four and eight weeks
of treatment.
CCDS 180622 3 PARIET (190617) API
In an active-controlled study of 202 patients treated with PARIET 20 mg once daily or omeprazole
20 mg once daily for up to eight weeks, PARIET was as effective as omeprazole in producing
endoscopic healing. The percentages of patients healed at endoscopy at four and eight weeks
are given in Table 1.
Table 1. Erosive or Ulcerative GORD
Percentage of Patients Healed
Week PARIET 20 mg od (n=100) Omeprazole 20 mg od (n=102)
4 81% 81%
8 92% 94%

PARIET 20 mg once daily was also as effective as omeprazole 20 mg once daily in reducing
heartburn frequency, in improving daytime and night-time heartburn severity, and in reducing the
amount of antacid taken per day.
Prevention of Relapse of Gastro-Oesophageal Reflux Disease (GORD): The prevention of
relapse in patients with erosive or ulcerative GORD previously healed with gastric anti-secretory
therapy was assessed in two U.S. multi-centre, double-blind, placebo-controlled studies of 52
weeks duration. The two studies of identical design randomised 209 and 285 patients
respectively, to receive either 10 mg or 20 mg of PARIET, or placebo once daily. In both studies
PARIET was significantly superior to placebo in prevention of relapse of GORD.
In both multicentre trials, PARIET 10 mg once daily and 20 mg once daily were significantly more
effective than placebo in preventing the recurrence of heartburn frequency (p<0.001) as well as
improving day-time (p<0.001) and night-time (p<0.003) heartburn severity.
In the actively controlled European study, 243 patients were treated with a fixed dose of either
omeprazole 20 mg once daily, or PARIET 10 mg or 20 mg once daily. Treatment with both 10 mg
and 20 mg PARIET were as effective as omeprazole 20 mg in preventing GORD relapse
(p=0.5216 and p=0.8004 respectively). See Table 2.
Table 2. Erosive or Ulcerative GORD
Percentage of Patients Relapse Free
Week PARIET 10 mg od (n=82) PARIET 20 mg od (n=78) Omeprazole 20 mg od (n=83)
52 95% 96% 95%

PARIET 10 mg and 20 mg once daily were also as effective as omeprazole 20 mg once daily in
reducing heartburn frequency, and improving daytime and night-time heartburn severity.
Symptomatic Gastro-Oesophageal Reflux Disease (GORD): On-demand treatment was
assessed in a European multicentre, double-blind placebo-controlled randomised withdrawal
study (n=418) in endoscopically negative patients.
Following an acute open-label phase, patients were randomised to receive rabeprazole 10 mg or
placebo taken once daily, when required, over a six month period. Efficacy of rabeprazole 10 mg
on-demand, in patients with complete heartburn relief at baseline was primarily evaluated by the
unwillingness to continue the trial because of inadequate heartburn control. Overall, the
proportion of patients discontinuing due to inadequate heartburn control was significantly higher
for placebo (20%) compared to rabeprazole (6%) (p<0.00001).
Patients were instructed to take study drug until they had experienced a full 24 hours free of
heartburn, most patients in the rabeprazole group had maximum episode duration of 4 days or
less. In addition, antacid use was about 2-fold higher in the placebo group than in the rabeprazole
group (p=0.0011). Treatment failure was associated with an increased antacid consumption.
Treatment of Duodenal Ulcers: In a US study (n=100) PARIET 20 mg once daily was
significantly superior to placebo in producing healing of endoscopically defined duodenal ulcers
(p=0.001) after four weeks’ treatment

CCDS 180622 4 PARIET (190617) API

Patients treated for four weeks with PARIET 20 mg once daily reported significantly less ulcer
pain frequency (p<0.001). After 7 days’ treatment with PARIET 20 mg once daily, patients
reported significantly less daytime (p=0.013) and night-time (p=0.003) ulcer pain severity than
patients treated with placebo. This difference continued for the whole study period. Additionally,
PARIET 20 mg once daily was significantly more effective than placebo in reducing daily antacid
use (p<0.001).
In the ranitidine-controlled trial, 375 patients with endoscopically defined duodenal ulcers were
treated with PARIET 20 mg once daily or ranitidine 150 mg twice daily for up to four weeks.
PARIET 20 mg once daily was significantly more effective than ranitidine 150 mg twice daily at
producing complete healing of duodenal ulcers after 2 and 4 weeks (p=0.002 and p=0.017
respectively).
PARIET 20 mg once daily was also significantly more effective than ranitidine 150 mg twice daily
in producing complete resolution of ulcer pain frequency (week 2, p=0.006), in alleviating night-
time ulcer pain severity (week 2, p=0.044), and in reducing antacid consumption (p=0.037).
In patients with endoscopically defined duodenal ulcers treated for up to four weeks, PARIET 20
mg once daily was as effective as omeprazole 20 mg once daily in producing healing of duodenal
ulcers. The percentages of patients with endoscopic healing at two and four weeks are shown in
Table 3.
Table 3. Duodenal Ulcers
Percentage of Patients Healed
Week PARIET 20 mg od (n=102) Omeprazole 20 mg od (n=103)
2 69% 61%
4 98% 93%

PARIET 20 mg once daily was significantly (p=0.038) more effective than omeprazole 20 mg once
daily in reducing daytime ulcer pain severity at week 4. In this trial PARIET 20 mg once daily also
proved to be as effective as omeprazole 20 mg once daily at reducing ulcer pain frequency and
night-time ulcer pain.
Treatment of Gastric Ulcers: PARIET was found to be significantly (p=0.002) superior to
placebo in producing endoscopically defined healing of gastric ulcers after 6 weeks in a placebo-
controlled study assessing the effectiveness of PARIET 20 mg once daily versus placebo
(p<0.001).
The rates of endoscopic healing of gastric ulcers in patients treated with PARIET 20 mg once
daily (n=184) and ranitidine 150 mg two times per day (n=180) were found to be equivalent after
three and six weeks of treatment.
In a European multicentre study comparing PARIET 20 mg (n=113) to omeprazole 20 mg
(n=114), the rates of endoscopic healing of gastric ulcers were found to be equivalent with the
two treatments at three and six weeks. See Table 4.
Table 4 Gastric Ulcers
Percentage of Patients Healed
Week PARIET 20 mg od (n=143) Omeprazole 20 mg od (n=114)
3 58% 61%
6 91% 91%

PARIET was significantly superior to omeprazole in reducing ulcer pain frequency (week 6,
p=0.006), in improving daytime ulcer pain severity (week 3, p=0.023), and in providing complete
resolution of night-time ulcer pain severity (week 6, p=0.022).

CCDS 180622 5 PARIET (190617) API

H. pylori eradication: In a multicentre, randomised, controlled European study conducted to
establish the efficacy of PARIET based triple therapy for H pylori eradication in patients with peptic
ulcer disease, the combination: PARIET 20mg twice daily with clarithromycin 500mg twice daily
and amoxycillin 1g twice daily for a total of 7 days (n = 83), achieved an eradication rate of 94%
and a healing rate for duodenal ulcers of 91%.

INDICATIONS
PARIET is indicated for:
• Treatment and prevention of relapse of gastro-oesophageal reflux disease
• Symptomatic treatment of gastro-oesophageal reflux disease
• Treatment of duodenal ulcers
• Treatment of gastric ulcers.

Patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal
anti-inflammatory drugs (NSAIDs) usually require treatment with antimicrobial agents in addition
to antisecretory drugs whether on first presentation or on recurrence.

PARIET is also indicated, in combination with clarithromycin and amoxycillin, for:

• Eradication of Helicobacter pylori in patients with peptic ulcer disease or chronic gastritis
• Healing of peptic ulcers in patients with Helicobacter pylori associated ulcers.

CONTRAINDICATIONS
PARIET is contraindicated in patients with known hypersensitivity to rabeprazole sodium, proton
pump inhibitors, or any ingredient of this product.

PRECAUTIONS
Symptomatic response to therapy with PARIET does not preclude the presence of gastric
malignancy; therefore the possibility of malignancy should be excluded prior to commencing
treatment with PARIET.
Patients using an on-demand regimen for symptomatic GORD should be further reviewed and/or
investigated if symptoms persist beyond 6 months.
Acute Interstitial Nephritis
Acute interstitial nephritis has been observed in patients taking proton-pump inhibitors (PPIs)
including rabeprazole sodium. Acute interstitial nephritis may occur at any point during PPI
therapy and is generally attributed to an idiopathic hypersensitivity reaction. Discontinue
rabeprazole sodium if acute interstitial nephritis develops.
Cyanocobalamin (vitamin B-12) Deficiency
Daily treatment with acid-suppressing medicines over a long period of time (e.g. longer than 3
years) may lead to malabsorption of cyanocobalamin (vitamin B-12) caused by hypo- or
achlorhydria.
Use in Patients with Hepatic Impairment.
No dosage adjustment is necessary for patients with hepatic impairment. While no evidence of
significant drug related safety problems was observed in patients with hepatic impairment, it is
advised to exercise caution when treatment with PARIET is first initiated in patients with severe
hepatic dysfunction (see DOSAGE & ADMINISTRATION).
Hypomagnesemia
Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated
with PPIs. Serious adverse events include tetany, arrhythmias, and seizures. In most patients,
treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI.

CCDS 180622 6 PARIET (190617) API

For patients expected to be on prolonged treatment or who take PPIs with medications such as
digoxin or drugs that may cause hypomagnesemia (e.g. diuretics), health care professionals may
consider monitoring magnesium levels prior to initiation of PPI treatment and then periodically
while treatment continues (see ADVERSE REACTIONS).
Fractures
Observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with
an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture
was increased in patients who received high-dose, and long-term PPI therapy (a year or longer).
Concomitant use of Rabeprazole with Methotrexate
Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see
methotrexate prescribing information) may elevate and prolong serum levels of methotrexate
and/or its metabolite, possibly leading to methotrexate toxicities. In such high-doses methotrexate
administration, a temporary withdrawal of the PPI may be considered in some patients.
Clostiridium difficile
Treatment with proton pump inhibitors may possibly increase the risk of gastrointestinal infections
such as Clostridium difficile.
Subacute cutaneous lupus erythematosus
Subacute cutaneous lupus erythematosus (SCLE) has been reported with the use of PPIs. If
lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the
patient should seek medical help promptly and the health care professional should consider
stopping rabeprazole. The occurrence of SCLE with previous PPI treatment may increase the risk
of SCLE with other PPIs.
Fundic gland polyps
As with other PPIs, long-term use of rabeprazole is associated with an increased risk of fundic
gland polyps (see ADVERSE REACTIONS, Post-marketing data). Most fundic gland polyps are
asymptomatic. Patients with large or ulcerated polyps may be at risk of gastrointestinal bleeding
or small intestinal blockage. Use the lowest dose and shortest duration of PPI therapy appropriate
to the condition being treated.
Carcinogenicity, Mutagenicity and Impairment of Fertility
Note: In the following section, the relative exposure levels in animals have been calculated using a
human dose of 20mg/day, the maximum recommended PARIET dose for the treatment of GORD
and active gastro-duodenal ulcers. For H pylori eradication, the recommended dose of PARIET is
40 mg/day (20mg b.i.d.) for one week; this should be taken into account when reviewing exposure
figures.
In an 88/104 week carcinogenicity study in CD-1 mice, rabeprazole at oral doses up to 100
mg/kg/day did not produce any increased tumour occurrence. The highest tested dose produced
a systemic exposure to rabeprazole (AUC) of 1.40 µg.hr/mL which is 1.6 times the human
exposure at the recommended dose for GORD (20 mg/day).
In a 104-week carcinogenicity study in SD rats, males were treated with oral doses of 5, 15, 30
and 60mg/kg/day and females with 5, 15, 30, 60 and 120 mg/kg/day. Rabeprazole produced
gastric enterochromaffin-like (ECL) cell hyperplasia in male and female rats and ECL cell
carcinoid tumours in female rats at all doses. The lowest dose (5 mg/kg/day) produced a systemic
exposure to rabeprazole (AUC) of about 0.1 µg.hr/mL which is about 0.1 times the human
exposure at 20 mg/day. In male rats, no treatment-related tumours were observed at doses up
to 60 mg/kg/day producing a rabeprazole plasma exposure (AUC) of about 0.2 µg.hr/mL (0.2
times the human exposure at 20 mg/day).
Rabeprazole was positive in assays for gene mutations (the AMES test, forward gene mutation
tests in Chinese hamster ovary cells (CHO/HGPRT) and mouse lymphoma cells (L5178Y/TK+/-
)). Its demethylated-metabolite was also positive in the AMES test. Rabeprazole was negative
in assays for chromosomal damage (the in vitro Chinese hamster lung cell chromosome
aberration test, the in vivo mouse micronucleus test), and in vitro and ex vivo rat hepatocyte
unscheduled DNA synthesis (UDS) tests.

CCDS 180622 7 PARIET (190617) API

Rabeprazole at intravenous doses up to 30 mg/kg/day (plasma AUC of 8.8 µg.hr/mL, about 10
times the human exposure at 20 mg/day) was found to have no effect on fertility and reproductive
performance of male and female rats.
Use in Pregnancy
Category B1.
Teratology studies have been performed in rats at intravenous doses up to 50 mg/kg/day (plasma
AUC of 11.8 µg.hr/mL, about 13 or 6.5 times the human exposure at 20 mg/day and 40mg/day
respectively), and rabbits at intravenous doses up to 30 mg/kg/day (plasma AUC of 7.3 µg.hr/mL,
about 8 or 4 times the human exposure at 20 mg/day and 40mg/day respectively) and have
revealed no evidence of impaired fertility or harm to the foetus due to rabeprazole. There are no
adequate and well-controlled studies in pregnant women and post-marketing experience is very
limited. Rabeprazole sodium should be used in pregnancy only if the potential benefit justifies the
potential risk to the foetus.
Use in Lactation
Following intravenous administration of 14C-labelled rabeprazole to lactating rats, radioactivity in
milk reached levels that were about 2- to 7-fold higher than levels in the blood. Administration of
rabeprazole to rats in gestation and during lactation at doses of 400 mg/kg/day (about 195-or 85-
times a 20mg or 40mg human dose based on mg/m2) resulted in decreases in body weight gain
of the pups.
It is not known whether rabeprazole sodium is excreted in human breast milk and there are no
studies in lactating women. Since many drugs are excreted in milk and because of the potential
for adverse reactions to nursing infants from rabeprazole sodium, a decision should be made to
discontinue nursing or discontinue the drug, taking into account the importance of the drug to the
mother.
Interference with Laboratory Tests
PPI-induced decreases in gastric acidity may lead to increases in serum chromogranin A (CgA)
levels, which may lead to erroneous interpretations of laboratory results in investigations for
neuroendocrine tumors. To avoid this interference, temporarily stop PARIET treatment at least
14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high.

INTERACTIONS WITH OTHER MEDICINES

Effect of rabeprazole sodium on other drugs – demonstrated interactions
In vitro studies with human liver microsomes indicated that rabeprazole sodium is metabolised by
isoenzymes of CYP450 (CYP2C19 and CYP3A4).
Patients may need to be monitored when the following drugs are taken together with PARIET:
Cyclosporin: In vitro incubations employing human liver microsomes indicated that rabeprazole
inhibited cyclosporin metabolism with an IC 50 of 62 micromolar, a concentration that is over 50
times higher than the C max in healthy volunteers following 14 days dosing with 20 mg rabeprazole.
Although in vitro studies may not always be predictive of an in vivo status these findings indicate
that no interaction is expected between rabeprazole and cyclosporin.
Methotrexate: case reports, published population pharmacokinetic studies, and retrospective
analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high
dose; see methotrexate prescribing information) may elevate and prolong serum levels of
methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction
studies of methotrexate with PPIs have been conducted.
Digoxin: A 22% increase in trough digoxin levels was observed in normal subjects given both
drugs concomitantly.
Ketoconazole: A 33% decrease in ketoconazole levels was observed in normal subjects given
both drugs concomitantly.
Atazanavir: co-administration of atazanavir with other proton pump inhibitors resulted in a
substantial reduction in atazanavir exposure. The absorption of atazanavir is pH dependent.
Therefore, PARIET should not be co-administered with atazanavir.
CCDS 180622 8 PARIET (190617) API
Mycophenolate mofetil: co-administration of proton-pump inhibitors with mycophenolate mofetil in
healthy and transplant patients has been reported to reduce the exposure to the active metabolite,
mycophenolic acid. This is possibly due to a decrease in mycophenolate mofetil solubility at an
increased gastric pH. The clinical relevance of reduced mycophenolic acid exposure on organ
rejection has not been established in transplant patients receiving proton-pump inhibitors and
mycophenolate mofetil. Use rabeprazole sodium with caution in transplant patients receiving
mycophenolate mofetil.
Clopidogrel: Clopidogrel is metabolised to its active metabolite by CYP2C19. Inhibition of
CYP2C19 by rabeprazole would be expected to result in reduced drug levels of the active
metabolite of clopidogrel and a reduction in its antiplatelet activity and therefore its clinical efficacy.
Concomitant use of rabeprazole with clopidogrel should be discouraged.
Effect of rabeprazole sodium on other drugs – theoretical interactions
Rabeprazole sodium produces sustained inhibition of gastric acid secretion. An interaction with
compounds whose absorption depends on gastric pH may occur due to the magnitude of acid
suppression seen with rabeprazole sodium.
Effect of rabeprazole sodium on other drugs – potential interactions that have been
excluded
Studies in healthy subjects have shown that rabeprazole sodium does not have clinically
significant interactions with other drugs metabolised by the CYP450 system. These studies
included the drugs warfarin and theophylline (as single oral doses), phenytoin (as a single
intravenous dose with supplemental oral dosing), diazepam (as a single intravenous dose) and
amoxycillin (as single and multiple oral doses).
Taking PARIET with antacids produces no clinically relevant changes in plasma rabeprazole
sodium concentrations.
Plasma concentrations of rabeprazole and the active metabolite of clarithromycin are increased
by 24% and 50% respectively during concomitant administration. This is considered to be a useful
interaction during H. pylori eradication.

ADVERSE REACTIONS
Throughout this section, adverse reactions are presented. Adverse reactions are adverse events
that were considered to be reasonably associated with the use of rabeprazole based on the
comprehensive assessment of the available adverse event information.

Clinical trials
PARIET was generally well tolerated during clinical trials. The observed side effects have
generally been mild or moderate and transient in nature. In the majority of cases, the incidence
of the adverse events in the PARIET treatment group was equal to or less than that observed in
the placebo control treatment group.
Only headaches, diarrhoea, abdominal pain, asthenia, flatulence, rash and dry mouth have been
associated with the use of PARIET.
The adverse events, which may or may not be causally related to PARIET, reported in clinical
trials are listed below in descending order of frequency.
Common (> 1% and < 10%)
Nervous System: headache, dizziness.
Gastrointestinal: diarrhoea, nausea, abdominal pain, flatulence, vomiting, constipation.
Respiratory: rhinitis, pharyngitis, cough.
Musculoskeletal: non-specific pain, back pain, myalgia.
Skin: rash.
Other: asthenia, flu-like syndrome, infection, insomnia, chest pain.
Uncommon (≥ 0.1% and < 1%)

CCDS 180622 9 PARIET (190617) API

Gastrointestinal: dyspepsia, eructation, dry mouth.
Respiratory: sinusitis, bronchitis.
Musculoskeletal: arthralgia, leg cramps.
Urinary: urinary tract infection.
Other: fever, nervousness, somnolence, chills, peripheral oedema.
Rare (≥ 0.01% and < 0.1%)
Gastrointestinal: anorexia, gastritis, weight gain, stomatitis.
Skin: pruritis, sweating.
Special Senses: vision or taste disturbances.
Haematologic: leucocytosis.
Other: depression.

Post-marketing data
In addition to the adverse reactions reported during clinical studies and listed above, the following
adverse reactions have been reported during post-marketing experience.
Erythema and rarely bullous reactions, urticarial skin eruptions and acute systemic allergic
reactions, for example facial swelling, hypotension and dyspnoea have been reported in patients
treated with PARIET. These usually resolved after discontinuation of therapy.
Erythema multiforme, interstitial nephritis, gynaecomastia, myalgia and potential allergic reactions
including anaphylactic reactions have been reported rarely. Blood dyscrasia including
thrombocytopenia, neutropenia, leukopenia, pancytopenia, agranulocytosis and bicytopenia have
been reported rarely. Hypomagnesemia has also been reported rarely.
There have also been reports of increased hepatic enzymes and serious hepatic dysfunction such
as hepatitis and jaundice. Rare reports of hepatic encephalopathy have been received in patients
with underlying cirrhosis.
There have been very rare reports of toxic epidermal necrolysis (TEN), Stevens-Johnson
syndrome and bullous rashes including subacute cutaneous lupus erythematosus.
There have been post-marketing reports of bone fractures and post-marketing reports of subacute
cutaneous lupus erythematosus (SCLE) and fundic gland polyps (see PRECAUTIONS).
Gastrointestinal disorders
Frequency not known: Withdrawal of long-term PPI therapy can lead to aggravation of acid-
related symptoms and may result in rebound acid hypersecretion.

DOSAGE AND ADMINISTRATION

PARIET tablets should not be chewed or crushed, but should be swallowed whole. PARIET
tablets should be taken at the same time each day to facilitate treatment compliance. PARIET
was taken with or without food in the pivotal clinical trials.
Adults
Treatment of active Gastro-Oesophageal Reflux Disease (GORD): The recommended oral dose
for this condition is one 20 mg tablet to be taken once daily for four to eight weeks.
Prevention of Relapse of Gastro-oesophageal Reflux Disease (GORD): The recommended oral
dose for preventing relapse of GORD, once healing is achieved, is one 10 mg tablet to be taken
once daily.
If needed this dose should be increased to one 20 mg tablet to be taken once daily.
Symptomatic Treatment of Gastro-Oesophageal Reflux Disease (GORD): Treatment should
commence at 10 mg once daily in patients without oesophagitis. If no response, the dose should
be increased to 20 mg once daily for four weeks. If symptom control has not been achieved within
four weeks, the patient should be further investigated.

CCDS 180622 10 PARIET (190617) API

Once symptoms have resolved, subsequent symptom control can be achieved using an on-
demand regimen of one 10 mg tablet to be taken once daily, when needed. (see
PRECAUTIONS).
Treatment of active Duodenal Ulcer and Gastric Ulcer: The recommended oral dose for both
duodenal ulcer and gastric ulcer is one 20 mg tablet to be taken once daily.
Some patients with duodenal ulcer may respond to one 10 mg tablet taken once daily.
Most patients with active duodenal ulcer heal within four weeks. However a few patients may
require an additional four weeks of therapy to achieve healing.
Most patients with gastric ulcer heal within six weeks. However, again a few patients may require
an additional six weeks of therapy to achieve healing.
Eradication of H. pylori: Patients with gastro-duodenal ulcers or chronic gastritis due to H. pylori
infection should be treated with: PARIET 20 mg twice daily + clarithromycin 500 mg twice daily
and amoxycillin 1 g twice daily for seven days.
Eradication of H. pylori with this regimen has been shown to result in the healing of duodenal
or gastric ulcers without the need for continued ulcer therapy.
Use in Children
PARIET is not recommended for use in children as there is no experience of its use in this group.
Use in Elderly Patients
No dosage adjustment is necessary in elderly patients.
Use in Patients with Renal Impairment
No dosage adjustment is necessary for patients with renal impairment.
There are no data on the use of rabeprazole in combination with antibiotic regimens in patients
with renal impairment.
Use in Patients with Hepatic Impairment
Patients with mild to moderate hepatic impairment experience higher exposure to rabeprazole
sodium at a given dose than do healthy patients. Caution should be exercised in patients with
severe hepatic impairment (see PRECAUTIONS).
There are no data on the use of rabeprazole in combination with antibiotic regimens in patients
with hepatic impairment.

OVERDOSAGE
Experience to date with deliberate or accidental overdose is limited. The maximum established
exposure has not exceeded 60 mg twice daily, or 160 mg once daily. Effects are generally
minimal, representative of the known adverse event profile, and reversible without further medical
intervention. No specific antidote is known. Rabeprazole sodium is extensively protein bound
and is therefore not readily dialysable. As in any case of overdose, treatment should be
symptomatic and general supportive measures should be used.

PRESENTATION AND STORAGE CONDITIONS

PARIET is available as enteric coated tablets containing 10 mg rabeprazole sodium (equivalent
to 9.42 mg rabeprazole) or 20 mg rabeprazole sodium (equivalent to 18.85 mg rabeprazole).
PARIET 10 mg are pink, biconvex tablets, marked with “ε 241” in black ink on one side presented
in blister packs of 7 (starter pack only), 28 and 30 tablets.
PARIET 20 mg are light yellow, biconvex tablets, marked with “ε 243” in red ink on one side
presented in blister packs of 7, 28 and 30 tablets.
Not all pack sizes may be supplied.
Storage Conditions
PARIET tablets should be stored below 25°C. Do not refrigerate.

CCDS 180622 11 PARIET (190617) API

Tablets are presented in an aluminium/aluminium blister.

NAME AND ADDRESS OF THE SPONSOR

JANSSEN-CILAG Pty Ltd
1-5 Khartoum Rd
Macquarie Park NSW 2113
Australia

POISON SCHEDULE OF THE MEDICINE

Prescription Only Medicine

DATE OF FIRST INCLUSION IN THE ARTG:

31 October 2000

DATE OF MOST RECENT AMENDMENT:

17 June 2019
® PARIET is a trademark of Eisai Ltd.

CCDS 180622 12 PARIET (190617) API